| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2022389 | Regulatory Peptides | 2014 | 4 Pages |
•Serum adropin levels were significantly lower in AMI patients.•Lower adropin was the independent predictor for the presence of AMI.•Adropin might represent as a novel biomarker for predicting AMI onset.
ObjectiveAdropin is a recently identified bioactive protein that is important for energy homeostasis and maintaining insulin sensitivity. We sought to detect serum adropin levels in acute myocardial infarction (AMI) patients.MethodsWe enrolled 138 AMI patients, 114 stable angina pectoris (SAP) patients and 75 controls. Adropin levels were measured by enzyme-linked immunosorbent assay (ELISA).ResultsSerum adropin levels were significantly lower in patients with AMI compared with SAP patients or controls (P < 0.01). Multivariate logistic regression demonstrated that lower adropin was the independent predictor for the presence of AMI in coronary artery disease (CAD) patients (P < 0.01). Serum adropin levels were negatively associated with body mass index (BMI) (P < 0.01) and triglyceride levels (P < 0.05) in AMI patients.ConclusionDecreased serum adropin levels are associated with the presence of AMI in CAD patients. These results revealed that adropin might represent as a novel biomarker for predicting AMI onset in CAD patients.
